Depo-Provera Settlement Status: What the June 2026 Agreement Does—and Does Not—Confirm

The confirmed fact: there is a global agreement

On June 15, 2026, Judge M. Casey Rodgers signed Pretrial Order No. 30A in MDL 3140. The order says plaintiffs' lead counsel and Pfizer Inc., Pharmacia LLC, and Pharmacia & Upjohn Co. LLC entered an agreement. Under the court's description, plaintiffs with cases pending in the MDL who meet eligibility criteria agreed by the parties will have an opportunity to resolve their claims. That is a court-confirmed development, not a rumor or a lawyer-advertising estimate.

The precision of that sentence matters. The order refers to an opportunity, to cases already pending in the MDL, and to privately agreed criteria. It does not say every filed plaintiff accepted an offer. It does not say money has been distributed. It does not identify the amount available to any participant. It also does not describe agreements, if any, with every defendant named across the broader litigation. The safest label is “global agreement disclosed; individual implementation terms not public in the cited order.”

What the court did because of the agreement

The court postponed ruling on the defendants' pending motion for summary judgment based on federal preemption. It also moved the Rule 702 evidentiary hearing from June 24–25 to July 27, 2026. Those are concrete procedural consequences. Postponement is not a ruling for either side, and rescheduling is not cancellation. Preemption and expert admissibility remain distinct issues with potential consequences for claims that do not resolve.

Judge Rodgers said the Rule 702 hearing and ruling would proceed in the ordinary course because the global agreement, once finalized, would not resolve all cases. The hearing concerns general-causation expert testimony. The order also explains which existing plaintiffs will be bound by that ruling and reserves future direction for some later-filed cases. In other words, the agreement created a resolution path for a defined group while the court preserved an adjudication path for others.

What remains private or unresolved

Pretrial Order No. 30A does not publish an allocation formula, injury tiers, proof standards beyond the court's existing threshold process, release language, appeal rights, lien procedures, payment timing or a claims administrator. It does not state whether an individual was offered a specific amount. None of those blanks can responsibly be filled with figures borrowed from unrelated drug MDLs or estimates generated from verdicts in other products.

Eligibility is also not something a public website can decide from the order. Existing court procedures required initial documentary proof of DMPA use and an alleged meningioma injury, but satisfying a filing requirement is not necessarily the same as satisfying private agreement criteria. Product identity, dates of use, diagnosis, case status and representation may all be relevant in real administration, yet the public order does not authorize a universal checklist. Participating counsel or an authorized administrator is the appropriate source for case-specific terms.

Settlement language that often gets blurred

A negotiated agreement, a signed individual release, a dismissal and a payment are four different milestones. A global framework can exist before every claimant receives or accepts an offer. Courts can keep litigating common questions while a program is implemented. Some plaintiffs may be outside its scope or may choose another path, depending on actual terms. Reporting that says “the cases settled” without these distinctions gives readers more certainty than the order supplies.

The difference between a settlement and a verdict is equally important. A settlement generally resolves claims without a judicial finding that defendants are liable. The cited order records no admission of wrongdoing and makes no individual causation determination. Likewise, the FDA's 2025 meningioma warning is a regulatory label change, not a damages award. Each source answers a different question: the label describes approved risk information; the court order describes procedure; an agreement governs consenting parties under its own terms.

The status as of July 10, 2026

The verified status is mixed, not mysterious: a global agreement has been disclosed for qualifying plaintiffs with pending MDL cases, its detailed terms are not in the public order, unresolved cases remain, and a Rule 702 hearing is listed for July 27. JPML separately reported 5,830 pending federal actions on July 1. The size of that inventory should not be equated with the number of agreement participants because the order supplies no such count.

The next reliable updates will come from a filed court order, an official administrator communication provided to participants, or case-specific counsel—not from an anonymous payout calculator. Readers should look for whether the July hearing occurs, whether the court enters an admissibility ruling, whether preemption briefing resumes, and whether public filings further define how nonparticipating or ineligible actions proceed. Until then, stating that exact values or universal deadlines are known would go beyond the record.

Reader questions

Frequently asked questions